Full text
Earnings transcript
Read the complete earnings call transcript.
EXEL
Exelixis, Inc.
$52.99
1.25
(2.42%)
| Exchange: | NASDAQ |
| Market Cap: | 13.319B |
| Shares Outstanding: | 1.988M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Michael Morrissey | |||||
| Full Time Employees: | 1147 | |||||
| Address: |
| |||||
| Website: | https://www.exelixis.com |
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company’s developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin’s lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,830,208 | 2,168,701 | 2,320,126 |
| Gross Profit | 1,757,661 | 2,092,485 | 2,236,429 |
| EBITDA | 196,602 | 718,752 | 921,756 |
| Operating Income | 170,885 | 604,617 | 872,191 |
| Net Income | 207,765 | 521,267 | 782,570 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 2,942,357 | 2,947,690 | 2,844,423 |
| Total Liabilities | 678,445 | 703,487 | 683,104 |
| Total Stockholders Equity | 2,263,912 | 2,244,203 | 2,161,319 |
| Total Debt | 189,944 | 190,823 | 173,038 |
| Cash and Cash Equivalents | 262,994 | 217,374 | 482,488 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 333,324 | 699,971 | 884,267 |
| Capital Expenditure | -162,969 | 0 | 0 |
| Free Cash Flow | 170,355 | 699,971 | 884,267 |
| Net Income | 207,765 | 521,267 | 782,570 |
| Net Change in Cash | -239,683 | -45,620 | 265,114 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,781,362.545 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 3,133,086.909 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 2,979,520.111 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,656,036.583 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,865,454.954 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,774,020.547 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,004,593.559 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,173,350.575 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,099,668.767 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 730,057.384 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 822,378.671 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 782,070.163 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 3.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.160 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 3.560 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 10 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: EXEL has demonstrated consistent revenue growth as reported in recent income statements, reflecting robust demand for its products or services within the industry. This aligns with positive industry trends indicated by sector performance metrics.
- Healthy Cash Flow: The cash flow statements highlight strong net cash provided by operating activities and positive free cash flow, indicating operational efficiency and the ability to fund growth initiatives or return value to shareholders.
- Solid Balance Sheet: Balance sheet data shows a favorable current ratio and manageable debt-to-equity ratio, suggesting financial stability and the capacity to weather economic downturns compared to industry averages.
- Positive Earnings Call Insights: The latest earnings call transcript reflects management’s confidence in sustained growth, with key financial results meeting or exceeding expectations, reinforcing investor trust in strategic execution.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates EXEL intrinsic value between $34.78 – $59.16 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about EXEL valuation
Is Exelixis, Inc. (EXEL) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Exelixis, Inc. (EXEL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is EXEL a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EXEL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is EXEL’s P/E ratio?
You can see EXEL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for EXEL?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is EXEL a good long-term investment?
Whether EXEL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
EXEL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.42
Trading Metrics:
| Open: | 52.53 | Previous Close: | 51.74 | |
| Day Low: | 52.01 | Day High: | 53.28 | |
| Year Low: | 33.76 | Year High: | 53.28 | |
| Price Avg 50: | 47.02 | Price Avg 200: | 42.9 | |
| Volume: | 1.745M | Average Volume: | 2.647M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeEXEL full analysis
Welcome to MARKETSNAP’s SWOT analysis for Exelixis! If you’re a long-term investor looking to build wealth and dig into some promising biotech opportunities, you’re in the right place. Today, we’re breaking down Exelixis, a company that’s been making waves in the oncology space. Let’s dive into who they are, what’s been happening with them lately, and then get into the meat of our SWOT analysis to see if this stock deserves a spot in your portfolio. First off, for those…
